IGC Pharma AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% at AAIC
IGC•IGC Pharma's AHA AI platform cut Alzheimer's data harmonization time by 90%, reducing manual processing from 28 hours to 2.5 hours in a test with 100 variables. The company will present this and six other AI-driven tools for speech biomarkers, EHR mining, and predictive analytics at AAIC 2026.
1. AAIC 2026 Presentations
IGC Pharma will showcase seven AI-driven presentations at the Alzheimer’s Association International Conference (July 12–15, London), highlighting agentic automation, speech-based cognitive biomarker models, electronic health record mining, predictive analytics and multi-omics data integration to accelerate drug discovery and clinical workflows.
2. AHA Platform Efficiency
The centerpiece AHA™ platform employs a patent-pending multi-agent architecture to harmonize complex Alzheimer’s datasets, cutting a representative 100-variable workflow from 28 hours of manual processing to 2.5 hours with human verification, a 90% reduction in internal tests with comparable external beta feedback.
3. Clinical and Development Implications
IGC Pharma’s lead asset, IGC-AD1, has achieved full randomization in its Phase 2 CALMA trial for Alzheimer’s agitation, and the company plans to leverage its AI portfolio to streamline cohort generation, patient stratification and data integration for Phase 3 and registration-enabling studies.
